AstraZeneca divests GI drug for $215m
This article was originally published in Scrip
Executive Summary
AstraZeneca continues efforts to streamline its non-core commercial portfolio with the divestment of global rights, outside the US, to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease and ulcerative colitis.